Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 1 35 versus MIUDELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 1 35 versus MIUDELLA.
CYCLAFEM 1/35 vs MIUDELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
None Documented
None Documented
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive